COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00331097
Recruitment Status : Completed
First Posted : May 29, 2006
Last Update Posted : March 28, 2017
Information provided by (Responsible Party):
National Cancer Institute, Naples

Brief Summary:
The purpose of this study is to compare disease free survival of elderly breast cancer patients treated with standard adjuvant chemotherapy (CMF) versus experimental adjuvant chemotherapy (weekly docetaxel).

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: docetaxel Drug: cyclophosphamide Drug: methotrexate Drug: 5-fluorouracil Phase 3

Detailed Description:

Adjuvant combination chemotherapy, given after breast cancer surgery, has been established as the standard approach to reduce the risk of breast cancer recurrence in those patients at intermediate or high risk for recurrence. However, since elderly patients have been underrepresented in past clinical trials, the optimal adjuvant therapy for elderly patients at risk for recurrence has not yet been defined.

Docetaxel is one of the most active drugs for patients with metastatic breast cancer and several trials are evaluating its efficacy in the adjuvant setting. Administration of docetaxel on a weekly schedule is effective and well tolerated in women with metastatic breast cancer.

In this study, patients from ages 65 to 80 will be randomized to one of two treatment strategies:

  • standard adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate, and 5-fluorouracil given intravenously on days 1 and 8 of each cycle)
  • experimental adjuvant chemotherapy with weekly docetaxel (given intravenously on days 1,8, and 15 of each cycle)

In both treatment strategies:

  • 4 cycles of chemotherapy will administered for patients at least 10% positive for ER or PgR, and 6 cycles will administered for patients expressing < 10% ER or PgR
  • patients with any positive expression of ER or PgR will receive adjuvant hormonal therapy with tamoxifen (20mg/day for 5 years) after concluding chemotherapy
  • adjuvant radiation therapy will be given to patients who are candidates at the conclusion of chemotherapy and within 6 months of surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adjuvant Chemotherapy in Elderly Patients With Breast Cancer: Weekly Docetaxel vs. CMF
Study Start Date : July 2003
Actual Primary Completion Date : May 2014
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Docetaxel

Arm Intervention/treatment
Active Comparator: A
Standard chemotherapy with CMF
Drug: cyclophosphamide
600 mg/m2 intravenously days 1, 8 every 28 days

Drug: methotrexate
40 mg/m2 intravenously days 1 and 8 every 28 days

Drug: 5-fluorouracil
600 mg/m2 intravenously days 1 and 8 every 28 days

Experimental: B
Weekly docetaxel
Drug: docetaxel
35 mg/m2 intravenously on days 1, 8, and 15 every 28 days

Primary Outcome Measures :
  1. disease free survival [ Time Frame: at 5 years ]

Secondary Outcome Measures :
  1. toxicity [ Time Frame: weekly ]
  2. compliance [ Time Frame: every 3 weeks ]
  3. quality of life [ Time Frame: baseline and every 3 weeks during therapy ]
  4. overall survival [ Time Frame: at 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years to 80 Years   (Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed invasive unilateral breast cancer
  • Age > 65 and < 80 years
  • Intermediate-high risk of recurrence according to St. Gallen criteria: ER negative and PgR negative, or axillary lymph node metastasis, or tumor size > 2 cm, or tumor grade 2 or 3 (intermediate or high)

Exclusion Criteria:

  • Performance status >1
  • Distant metastasis
  • Concomitant malignancy or malignancy within previous 5 years (except basal cell or spinocellular skin cancer and in situ cervical cancer if they have been adequately treated
  • Previous breast cancer treatment
  • Neutrophils < 2000/mm3 or platelets < 100000/mm3 or haemoglobin < 10 g/dl
  • Creatinine > 1.25 the upper normal limit
  • GOT and-or GPT and/or bilirubin > 1.25 the upper normal limit
  • Concomitant conditions that contraindicate the use of the drugs in the protocol
  • Incapacity or refusal to provide informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00331097

Layout table for location information
Azienda Sanitaria S. Giuseppe Moscati
Monteforte Irpino, AV, Italy
Azienda Ospedaliera G. Rummo
Benevento, BN, Italy
Policlinico Monteluce
Sant'Andrea delle Frate, PG, Italy
Azienda Ospedaliera Cardarelli
Napoli, Italy, 80131
Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C
Napoli, Italy, 80131
Università Federico II, Cattedra di Oncologia Medica
Napoli, Italy
Az. Osp. Treviglio - Caravaggio
Treviglio, Italy
Ospedale S. Luca ASL SA 3
Vallo della Lucania, Italy
Sponsors and Collaborators
National Cancer Institute, Naples
Layout table for investigator information
Principal Investigator: Andrea De Matteis, M.D. NCI Naples, Division of Medical Oncology C
Principal Investigator: Giuseppe D'Aiuto, M.D. NCI Naples, Division of Surgical Oncology A
Principal Investigator: Francesco Perrone, M.D., Ph.D. NCI Naples, Clinical Trials Unit
Publications of Results:
Other Publications:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: National Cancer Institute, Naples Identifier: NCT00331097    
Other Study ID Numbers: ELDA
First Posted: May 29, 2006    Key Record Dates
Last Update Posted: March 28, 2017
Last Verified: March 2017
Keywords provided by National Cancer Institute, Naples:
adjuvant therapy
intermediate risk
high risk
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antimetabolites, Antineoplastic
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors